We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email :PharmaSources@imsinoexpo.com
Whatsapp :+86-13621645194
Category:Finished Dosage > Digestive System Preparations Product Name:Lansoprazole for injection 30mg CAS No.:/ Standard:ChP, BP, EP Price(USD):0.00 Company:Sichuan Omnis Pharmaceutical Co., Ltd.
Factory Location: No.343, HeZuo Road, West Hi-Tech Zone, 611731, Chengdu, Sichuan, China
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: T/T
Active ingredient: Lansoprazole Description: White or off-white porous mass.
Dosage Form: lyophilized powder for injection Indications: Treatment for duodenal ulcer associated with hemorrhage while not suitable for oral administration. Strength: 30mg
Storage: Kept under a condition of sealed, free from light and not exceed 25oC. Packaging: Unopened glass vials, 1vial/box, 400 boxes/carton (Can be customized) Shelf life: 24 months Dosage and administration
Intravenous infusion is applied, normally 30mg for adults once and 2 times a day for no more than 7 days. Once the patient can take the drug orally, lansoprazole oral preparation should be used for a change. Prior to use, add 5ml of sterile water for injection into the vial to dissolve the content completely, next be added into a 100ml of 0.9% sodium chloride injection for dilution, and then followed by intravenous infusion. The recommended administration time should be not less than 30 minutes. Precaution
(1) When using this product in intravenous infusion, a filter with a pore size of 1.2μm should be provided in order to remove precipitates that may be generated during infusion. These precipitates may cause microvascular embolism with serious consequences.
(2) In any dangerous cases where there is an eruptive or gushing bleeding or vascular exposure, endoscopic hemostasis should be used.
(3)This product is only used for intravenous infusion. After dissolution, it should be used immediately and storage is prohibited. Mixing for intravenous infusion with liquids other than 0.9% sodium chloride injection and other drugs is not allowed.
(4) If the hemostatic effect is achieved within the first 3 days after treatment with this product, oral administration should be used instead of intravenous administration. Unlimited intravenous administration is not allowed. Contraindication
1. Do not use this product in patients who are allergic to lansoprazole and any ingredient of it.
2. Patients using atazanavir sulfate are prohibited from using this product. Child medication: The safety of children using this product has not been determined and there is no experience in using it. Elderly medication: caution. Overdose: There is currently no clinical experience of drug overdose for reference, but lansoprazole cannot be removed from the circulatory system by hemodialysis.